FGFR | sciencenewsnet.in

Breaking News

Kansas Proving Grounds Partners with SkyScoutAI Innovations Inc. to Deploy AI-Powered Drones for Wildfire Solution at America’s First Carbon Neutral Industrial Park

Perinatal Transmission of HIV Can Lead to Cognitive Deficits

CSUF Grad from Zimbabwe Aims to Improve Access to Mental Health Services

Alzheimer’s Consortium set to bring experts and families together at ASU

Critical Minerals Recovery from Electronic Waste

The Pediatric Emergency Department at Joseph M. Sanzari Children’s Hospital Becomes the First Autism Certified Center in the State

Genetics predict type 2 diabetes risk and disparities in childhood cancer survivors

Landmark Conference Celebrating Betty Ford’s Legacy as First Lady, With Notable Expert Panels

New study points to racial and social barriers that block treatment for multiple myeloma

Artificial Intelligence Can Evaluate Cardiovascular Risk During CT Scan

24 Apr, 2024

ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

June 5, 2023 sarah JonasResearch Results

Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.

AACR 2023: Ohio State experts share new findings on immuno-oncology, ‘smart-drugs,’ obesity-related endometrial cancers and other research topics

April 12, 2023 sarah JonasResearch Tip Sheet

New smart-drug treatment options for pancreatic cancer, immuno-oncology treatments and real-time immune-monitoring strategies are among the research topics to be presented by investigators at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at the American Association for Cancer Research (AACR) annual meeting held April 14-19 at the Orange County Convention Center in Orlando, Florida.

NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology

July 23, 2020 sarah JonasAnnouncement

The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.